Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
In this study, the investigators are comparing dexamethasone ophthalmic insert (DEXTENZA®) to
the current standard of care, prednisolone acetate 1% eye drops, in a glaucoma population
receiving both cataract and minimally-invasive glaucoma surgery (MIGS). DEXTENZA® and
prednisolone acetate 1% drops are both steroids used to control inflammation after eye
surgery. DEXTENZA®'s method of delivery differs by offering a sustained release of steroid
that does not necessitate postoperative anti-inflammatory eye drops. The investigators
hypothesize that DEXTENZA® will be as safe as prednisolone acetate 1% drops and as effective
at controlling postoperative inflammation following concomitant cataract-MIGS in a glaucoma
population. The investigators also hypothesize that DEXTENZA® will be preferred by patients
over prednisolone acetate 1% drops.